News

April 10, 2012
Boston Therapeutics PAZ320 Interim Clinical Trial Safety Results

April 6, 2012
Boston Therapeutics Launches SUGARDOWN(R) Publicity Campaign

April 2, 2012
Boston Therapeutics Corporate Update

March 22, 2012
Boston Therapeutics Is Quoted as BTHE on the OTC Bulletin Board

March 2, 2012
Boston Therapeutics to Be Quoted as BTHE on the OTC Bulletin Board

January 24, 2012
Boston Therapeutics Announces Clinical Study Safety Results With SUGARDOWN(R) at University of Sydney

December 29, 2011
Boston Therapeutics Gets First Sales of SUGARDOWN™ in Italy

December 22, 2011
Boston Therapeutics Elects Dr. Henry Esber to Its Board of Directors

October 11, 2011
Boston Therapeutics to Start Clinical Trial in Type 2 Diabetes

August 18, 2011
Boston Therapeutics Completes Human Clinical Study with SUGARDOWN™ at University of Sydney

August 4, 2011
Boston Therapeutics Submits to FDA Abbreviated New Drug Application (ANDA)

July 28, 2011
Boston Therapeutics IpoxynTM Data to be Presented Today at Symposium at Massachusetts General Hospital

June 30, 2011
Boston Therapeutics Licenses to Advance Pharmaceutical Exclusive Rights to Commercialize Sugardown™ for Blood Sugar Management in China

June 21, 2011
Boston Therapeutics Completes Private Offering: Total Proceeds Raised $508,000

June 28, 2010
Boston Therapeutics, Inc. Submits SugarDown™ to the US Food and Drug Administration